Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Minghui Pharmaceutical (Shanghai) Limited is currently prosecuting matters in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action, which is assigned to 1 distinct examiner. This indicates a highly focused prosecution effort, with all active work concentrated on a single matter. The case is being handled within 1 distinct art unit, suggesting a specific technical niche for the pending claims. This concentration means that the company's current intellectual property strategy is not diversified across multiple examiners.
The busiest examiner for this portfolio is O DELL, DAVID K, who is responsible for 1 pending office action. Because the total number of pending office actions is 1, this examiner is the only individual currently reviewing the company's active applications. For practitioners, this means that the immediate results for the portfolio depend entirely on the interactions with this 1 distinct examiner. The presence of only 1 distinct art unit further emphasizes the concentrated nature of the current workload, as there are no other active matters to provide a broader perspective on the company's standing within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276342 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | O DELL, DAVID K | 2d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18276342 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | O DELL, DAVID K | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276342 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | O DELL, DAVID K | 1621 | §102§103§112 | Final Rejection | 2d overdue | Pending | Aug 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial